Cantor Fitzgerald Reduces Earnings Estimates for AbbVie

AbbVie Inc. (NYSE:ABBV) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a report released on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the company will earn $11.84 per share for the year, down from their previous forecast of $12.31. Cantor Fitzgerald has a “Overweight” rating and a $210.00 price objective on the stock. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Cantor Fitzgerald also issued estimates for AbbVie’s FY2026 earnings at $14.09 EPS.

Other equities analysts also recently issued reports about the company. Erste Group Bank raised AbbVie to a “strong-buy” rating in a research note on Monday, March 17th. Citigroup increased their target price on AbbVie to $205.00 and gave the stock a “hold” rating in a research note on Wednesday, June 11th. Bank of America increased their target price on AbbVie to $204.00 and gave the stock a “hold” rating in a research note on Monday, June 9th. BNP Paribas raised AbbVie to a “hold” rating in a research note on Thursday, May 8th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Eight equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $211.29.

AbbVie Stock Performance

Shares of ABBV stock opened at $190.74 on Thursday. The company has a market cap of $336.92 billion, a price-to-earnings ratio of 81.17, a price-to-earnings-growth ratio of 1.28 and a beta of 0.48. The stock has a 50 day simple moving average of $187.10 and a 200-day simple moving average of $188.78. AbbVie has a 12-month low of $163.81 and a 12-month high of $218.66. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.31 EPS.

Institutional Investors Weigh In On AbbVie

Several hedge funds have recently made changes to their positions in ABBV. Steel Grove Capital Advisors LLC boosted its holdings in AbbVie by 1.7% in the fourth quarter. Steel Grove Capital Advisors LLC now owns 3,110 shares of the company’s stock valued at $553,000 after acquiring an additional 52 shares during the last quarter. FF Advisors LLC boosted its holdings in AbbVie by 3.6% in the second quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after acquiring an additional 53 shares during the last quarter. Peninsula Wealth LLC boosted its holdings in AbbVie by 4.1% in the fourth quarter. Peninsula Wealth LLC now owns 1,360 shares of the company’s stock valued at $242,000 after acquiring an additional 54 shares during the last quarter. Private Management Group Inc. boosted its holdings in AbbVie by 1.9% in the first quarter. Private Management Group Inc. now owns 2,938 shares of the company’s stock valued at $616,000 after acquiring an additional 54 shares during the last quarter. Finally, Silicon Valley Capital Partners boosted its holdings in AbbVie by 10.8% in the first quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock valued at $118,000 after acquiring an additional 56 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 279.15%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.